A137 with maternal hypertension. Early diagnosis and treatment through regular antenatal check-up is a key factor to prevent PIH and its complications. Interventions to improve maternal health through information, education and counselling of women of child bearing age should be implemented.Objectives: Increased perioperative blood pressure (BP) variability in cardiac surgery is associated with negative clinical outcomes and increased health resource utilization (HRU). Clevidipine, an ultrashort-acting, arterial selective calcium channel blocker reduces BP variability and may reduce HRU in this setting. The current model evaluates the one year budget impact of adding clevidipine to an intravenous antihypertensive (IVAH) treatment mix in a sample US hospital. MethOds: A spreadsheet model was developed using treatment specific HRU data from a clevidipine clinical trial (ECLIPSE) in cardiac surgery. Treatment distribution for IVAH agents (clevidipine, nicardipine, nitroglycerin, and nitroprusside), case volumes and comparable IVAH dosages were obtained from the Premier Hospital database. Unit costs for IVAH are US Wholesale Acquisition Costs (WAC). Thirtyday event costs were from the published literature. The model inputs may be customized to more accurately represent a given healthcare system. Results: The base case assumed a sample hospital with 468 coronary artery bypass graft (CABG) cases and 322 heart valve (HV) cases annually. Clevidipine usage in the base case was minimal (0% in CABG; 1% in HV). The base case predicts a one year total cost of $19,045,453 with the largest proportion of costs from general ward, ICU and operative suite time (approx. 30%, 21%, and 20% respectively). One year IVAH costs totaled $93,958 or 0.5% of total costs. Increasing the proportion of cases receiving clevidipine to 5% for both procedures increased drug acquisition costs by $13,005 and decreased HRU-related costs by $48,439 for a net decrease in costs of $35,434 for one year. cOnclusiOns: This analysis predicts a net savings with an increase in clevidipine use. In this example case, a minimal increase in IVAH costs was offset by savings in HRU-related costs resulting from improved outcomes associated with reduced perioperative BP variability.